mProX™ Human CCRL2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human CCRL2 Stable Cell Line (S01YF-0923-PY54). Click the button above to contact us or submit your feedback about this product.
Ronald (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Michelle (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 CCRL2 promotes the growth and clonogenicity of MDS cell lines.
Suppression of CCRL2 significantly diminishes clonogenic potential in MDS92 (P < 0.001; n = 9) and MDS-L (P < 0.001; n = 12) cells, with results presented as mean values alongside their standard deviations.
Ref: Karantanos, Theodoros, et al. "The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia." Science Advances 8.7 (2022): eabl8952.
Pubmed: 35179961
DOI: 10.1126/sciadv.abl8952
Research Highlights
Pich K, et al. "Effect of Vitamin D(3) on Chemerin and Adiponectin Levels in Uterus of Polycystic ." Cells, 2023.
Researchers investigated the potential impact of vitamin D(3) (VD(3)) supplementation on the levels of adipokines RARRES2 and ADIPOQ, and their receptors, in the uterus of rats with letrozole-induced polycystic ovary syndrome (PCOS). The study aimed to determine the effects of VD(3) on disrupted uterus structure and function in PCOS. Analysis of plasma levels, uterine transcript and protein expression showed that VD(3) supplementation returned RARRES2 and ADIPOQ levels in PCOS rats to those of control rats. Furthermore, VD(3) treatment resulted in changes in the expression of RARRES2, its receptors, and adiponectin and its receptors, indicating a potential new mechanism of VD(3) action in the uterine physiology of PCOS rats.
Pubmed:
37626836
DOI:
10.3390/cells12162026
Kusamura S, et al. "A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS ." Biomedicines, 2023.
The study aimed to investigate the mechanisms involved in immune surveillance evasion in a rare disease with poor molecular characterization. The role of KRAS and GNAS mutations was explored in inducing GM-CSF expression and enhancing cAMP and A2AR signaling. Immunohistochemistry and nanostring nCounter technology were used to study the expression of immune-related molecules in 40 Pseudomyxoma peritonei patients classified by their risk level. The results showed the expression of immune suppressive factors such as GM-CSF, A2AR, and PD-L1, which were not related to the mutational status of GNAS and KRAS. The tumor microenvironment also exhibited the presence of various immune cell populations. However, the expression of CD163 in tumor cells was associated with poor prognosis. A set of potential prognostic biomarkers, including CD163, was identified for further investigation. These findings suggest that GM-CSF, A2AR, and PD-L1 could be potential therapeutic targets, and CD163 may serve as a prognostic biomarker in Pseudomyxoma peritonei.
Pubmed:
37509688
DOI:
10.3390/biomedicines11072049
